Bulletin
Investor Alert

CRISPR Therapeutics AG

NAS: CRSP

GO
/marketstate/country/us

After Hours

/zigman2/quotes/201181046/composite

$

63.90

Change

+0.74 +1.17%

Volume

Volume 35,809

Sep 23, 2022, 7:53 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/201181046/composite

Previous close

$ 64.90

$ 63.16

Change

-1.74 -2.68%

Day low

Day high

$61.78

$64.59

Open
Open: 63.88

52 week low

52 week high

$42.51

$117.84

Open

Market cap

$4.93B

Average volume

1.21M

P/E ratio

N/A

Rev. per Employee

$31,334

EPS

-8.23

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/crsp

MarketWatch News on CRSP

  1. Crispr Therapeutics stock price target raised to $69 from $55 at Stifel Nicolaus

    7:46 a.m. Aug. 9, 2022

    - Tomi Kilgore

  2. Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

    4:25 p.m. June 23, 2022

    - Barron's Online

  3. CRISPR Therapeutics downgraded to in line from outperform at Evercore ISI

    6:23 a.m. June 23, 2022

    - Tomi Kilgore

  4. Crispr Therapeutics started at outperform with $98 stock price target at BMO Capital

    12:23 p.m. June 17, 2022

    - Tomi Kilgore

  5. Roku, Tesla, and Other Cathie Wood Favorites Are Falling

    10:21 a.m. June 13, 2022

    - Barron's Online

  6. FDA Advisors Support the First New Gene Therapy in Nearly 5 Years

    5:36 p.m. June 10, 2022

    - Barron's Online

  7. Crispr Therapeutics stock price target cut to $52 from $64 at Stifel Nicolaus

    8:12 a.m. May 10, 2022

    - Tomi Kilgore

  8. Crispr Therapeutics stock price target cut to $100 from $125 at Evercore ISI

    7:44 a.m. Feb. 17, 2022

    - Tomi Kilgore

  9. 20 Bargain Stocks to Buy Now

    8:38 p.m. Jan. 30, 2022

    - Barron's Online

  10. 4 Beaten-Down Biotech Stocks That Could Take Off

    4:07 p.m. Nov. 17, 2021

    - Barron's Online

  11. Beam Gets FDA Nod for First Gene-Editing Trial

    9:10 a.m. Nov. 9, 2021

    - Barron's Online

  12. Prime Is the Newest Gene Editing, and It's Getting Better

    7:11 p.m. Oct. 20, 2021

    - Barron's Online

  13. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/crsp

Other News on CRSP

  1. Cryoport: A Rare Investing Opportunity

    7:11 p.m. Sept. 22, 2022

    - Seeking Alpha

  2. Crispr: Elucidating And Forecasting Key Developments

    4:54 a.m. Sept. 21, 2022

    - Seeking Alpha

  3. "The Era of the Gene-Edited Human Is Here"

    5:35 p.m. Sept. 19, 2022

    - Motley Fool

  4. 2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years

    10:15 a.m. Sept. 19, 2022

    - Motley Fool

  5. 2 Biotech Stocks That Could Make You Richer

    10:07 a.m. Sept. 17, 2022

    - Motley Fool

  6. ARKK: Refusing To Fall Below May Lows - Buy This Pullback

    2:13 p.m. Sept. 9, 2022

    - Seeking Alpha

  7. Crispr Therapeutics: Nearing Harvest Season

    2:19 p.m. Sept. 8, 2022

    - Seeking Alpha

  8. The Best Biotech Stock to Own in September

    10:30 a.m. Sept. 6, 2022

    - Motley Fool

  9. 3 Biotech Stocks You Can Buy and Hold for the Next Decade

    10:23 a.m. Aug. 29, 2022

    - Motley Fool

  10. 3 Growth Stocks Poised to Skyrocket

    6:08 a.m. Aug. 27, 2022

    - Motley Fool

  11. Loading more headlines...
/news/pressrelease/company/us/crsp

Press Releases on CRSP

  1. CRISPR Therapeutics to Host Innovation Day on June 21, 2022

    8:00 a.m. May 31, 2022

    - GlobeNewswire

  2. Why Orphan Drug Designation Offers Several Benefits

    8:01 a.m. May 18, 2022

    - Financial News Media

  3. Why Orphan Drug Designation Offers Several Benefits

    8:00 a.m. May 18, 2022

    - PR Newswire - PRF

  4. Loading more headlines...

Rates »

Link to MarketWatch's Slice.